TEK and dengue disease: Our findings highlight the central role of hyperinflammation in determining outcomes from dengue shock; the data suggest that anti-IL-1 and anti-IL-6 immune modulators and Tie2 agonists may be considered as candidates for therapeutic trials in severe dengue.